Logos Global Management LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001792126

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 64 positions · Total reported value $1.66B · Top-10 concentration 47.8% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 75.9% · 15 new · 29 cut · 19 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.6% · vs SPY -15.7% · Prev Value $2.32B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -8.1% · vs SPY -10.3% · Latest Value $1.66B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Logos Global Management LP disclosed 64 equity positions with a combined reported value of $1.66B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 47.8% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were PRAX ($123.77M), RVMD ($123.16M), IDYA ($109.50M). By sector, the heaviest allocations are Health Care 98.5%, Industrials 0.4%. Versus the prior quarter, allocation shifted away from Health Care (-0.6pp).

Versus the prior quarter, Logos Global Management LP opened 15 new positions, trimmed 29 and fully exited 19, a turnover rate of 75.9% of positions. The portfolio's overlap with the prior quarter was 59% of names.

The largest new positions opened in Q3 2026 were MDGL ($50.40M), NBIX ($35.46M), AXSM ($32.27M).

Of the 19 positions fully exited versus the prior quarter, the largest were CLDX ($78.14M), MLYS ($28.33M), XENE ($27.16M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • MDGL MADRIGAL PHARMACEUTICALS INC · $50.40M
  • NBIX NEUROCRINE BIOSCIENCES INC · $35.46M
  • AXSM AXSOME THERAPEUTICS INC. · $32.27M
  • DARE YARROW BIOSCIENCE INC · $23.11M
  • SRPT SAREPTA THERAPEUTICS INC · $18.22M
  • BHVN BIOHAVEN LTD · $13.35M
  • ENTX ENTERA BIO LTD · $12.84M
  • GRTX ELECTRA THERAPEUTICS INC · $11.25M

Fully Exited (vs previous quarter)

  • CLDX CELLDEX THERAPEUTICS INC NEW · prev qtr: $78.14M
  • MLYS MINERALYS THERAPEUTICS INC · prev qtr: $28.33M
  • XENE XENON PHARMACEUTICALS INC · prev qtr: $27.16M
  • FTH FAETH THERAPEUTICS INC · prev qtr: $18.05M
  • DBVT DBV TECHNOLOGIES S A · prev qtr: $15.01M
  • RYTM RHYTHM PHARMACEUTICALS INC · prev qtr: $13.88M
  • VOR VOR BIOPHARMA INC · prev qtr: $11.97M
  • SRRK SCHOLAR ROCK HLDG CORP · prev qtr: $11.00M

Insider Transactions (Form 4)

Latest Logos Global Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Logos Global Management LP is an SEC-registered 13F filer based in San Francisco, CA, United States. As of Q2 2026 it reported 68 US equity positions with a combined value of $2.32B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: SAN FRANCISCO, CA, United States
  • SEC registration: 801-117248 (status: Approved), registered 2019-08-26
  • Regulatory AUM (Form ADV): $2.25B as of 2026-04-22
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 5 private funds, of which 1 hedge funds

Portfolio Structure

  • 68 positions · $2.32B reported value (Q2 2026)
  • Top 10 holdings = 48.3% of reported value
  • Largest position: ERAS (ERASCA INC COM) at 9.6%
  • Average position size: $34.16M

Sector Tilt

  • Health Care 99.1%
  • Financials 0.1%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 25 new, 18 added, 19 reduced, 20 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 98.5%
Financials 0.2%
Other 0.8%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 425.00K $123.77M 7.44%
7.44%
Add
2 600.00K $123.16M 7.40%
7.40%
Reduce
3 2.85M $109.50M 6.58%
6.58%
Reduce
4 870.00K $86.15M 5.18%
5.18%
Reduce
5 975.00K $69.12M 4.16%
4.16%
Reduce
6 1.01M $66.44M 3.99%
3.99%
Add
7 650.00K $63.90M 3.84%
3.84%
Reduce
8 2.15M $53.64M 3.23%
3.23%
Reduce
9 100.00K $50.40M 3.03%
3.03%
New
10 1.08M $49.51M 2.98%
2.98%
Add
11 3.00M $48.33M 2.91%
2.91%
Add
12 6.00M $46.02M 2.77%
2.77%
Add
13 500.00K $44.02M 2.65%
2.65%
Reduce
14 1.35M $40.88M 2.46%
2.46%
Add
15 1.25M $40.02M 2.41%
2.41%
Add
16 2.50M $36.65M 2.20%
2.20%
Reduce
17 250.00K $35.46M 2.13%
2.13%
New
18 200.00K $33.96M 2.04%
2.04%
Reduce
19 175.00K $32.27M 1.94%
1.94%
New
20 1.00M $31.27M 1.88%
1.88%
Add
21 3.21M $27.72M 1.67%
1.67%
Hold
22 935.00K $25.41M 1.53%
1.53%
Reduce
23 750.00K $24.22M 1.46%
1.46%
Add
24 1.03M $23.11M 1.39%
1.39%
New
25 1.50M $23.00M 1.38%
1.38%
Add
26 1.45M $20.69M 1.24%
1.24%
Reduce
27 170.00K $20.61M 1.24%
1.24%
Reduce
28 1.50M $19.86M 1.19%
1.19%
Reduce
29 600.00K $19.37M 1.17%
1.17%
Reduce
30 1.00M $18.22M 1.09%
1.09%
New
31 1.50M $17.55M 1.05%
1.05%
Reduce
32 1.00M $16.91M 1.02%
1.02%
Reduce
33 500.00K $15.14M 0.91%
0.91%
Reduce
34 250.00K $13.83M 0.83%
0.83%
Reduce
35 1.00M $13.35M 0.80%
0.80%
New
36 350.00K $13.32M 0.80%
0.80%
Add
37 500.00K $12.91M 0.78%
0.78%
Reduce
38 4.41M $12.84M 0.77%
0.77%
New
39 1.00M $12.57M 0.76%
0.76%
Reduce
40 1.00M $12.44M 0.75%
0.75%
Reduce
41 850.00K $12.40M 0.75%
0.75%
Reduce
42 1.00M $11.25M 0.68%
0.68%
New
43 3.29M $11.02M 0.66%
0.66%
Hold
44 250.00K $9.60M 0.58%
0.58%
Reduce
45 1.00M $8.09M 0.49%
0.49%
Reduce
46 1.00M $7.39M 0.44%
0.44%
New
47 2.00M $7.38M 0.44%
0.44%
New
48 2.00M $6.54M 0.39%
0.39%
New
49 200.00K $6.52M 0.39%
0.39%
New
50 2.22M $5.71M 0.34%
0.34%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 60% R 60% F1 60% (modelled on 2026-Q1; 6/10 hit)

Low-confidence forecast This fund replaces about 49% of its Top-10 each quarter and backtests at F1 47% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 47% · recall 47% · F1 47% · avg rank error 4.0 · Top-10 turnover 49%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 60% 60% 60% CYTK · SRPT · APLS · IDYA · OLMA · ARGX · GPCR · IMVT · RYZB · RCKT ALNY · IDYA · IMCR · IMVT · OCUL · SRPT · OLMA · DYN · APLS · RCKT
2024-Q2 30% 30% 30% ALNY · IMCR · IDYA · IMVT · SRPT · OCUL · OLMA · APLS · DYN · SLN XBI · IDYA · ARGX · MRUS · RVMD · IRON · OCUL · OLMA · VERA · MLTX
2024-Q3 50% 50% 50% XBI · IDYA · ARGX · MRUS · RVMD · IRON · VERA · MLTX · OCUL · JANX IDYA · GPCR · RVMD · IRON · JANX · OLMA · PCVX · IMVT · CLDX · OCUL
2024-Q4 40% 40% 40% IDYA · GPCR · RVMD · JANX · IRON · OLMA · PCVX · IONS · ERAS · CLDX IDYA · JANX · RVMD · CYTK · VERA · BNTX · MRUS · ERAS · INSM · OCUL
2025-Q1 40% 40% 40% IDYA · JANX · RVMD · CYTK · VERA · ERAS · BNTX · MRUS · INSM · NBIX IDYA · RVMD · AKRO · JANX · NUVL · TEVA · XENE · KROS · IRON · BNTX
2025-Q2 50% 50% 50% IDYA · RVMD · AKRO · JANX · NUVL · TEVA · XENE · ETNB · KROS · SLNO XBI · IDYA · AKRO · RVMD · JAZZ · IRON · RNAM · KROS · TEVA · BIIB
2025-Q3 20% 20% 20% XBI · IDYA · AKRO · RVMD · JAZZ · IRON · RNAM · KROS · BIIB · TEVA AKRO · ARVN · RVMD · OCUL · CDTX · VSTM · ABVX · ERAS · MAZE · OLMA
2025-Q4 60% 60% 60% AKRO · ARVN · RVMD · CDTX · VSTM · OCUL · MAZE · ABVX · DYN · ERAS PRAX · OLMA · RVMD · CDTX · ABVX · ERAS · OCUL · GPCR · IRON · MAZE
2026-Q1 60% 60% 60% PRAX · OLMA · RVMD · CDTX · ABVX · ERAS · OCUL · MAZE · TNGX · GPCR RVMD · ERAS · IDYA · PRAX · CNTA · ABVX · TNGX · CYTK · OLMA · UTHR
2026-Q2 ★ 60% 60% 60% RVMD · ERAS · IDYA · PRAX · CNTA · ABVX · TNGX · CYTK · MDGL · IMCR ERAS · ABVX · RVMD · IDYA · BNTX · VERA · TNGX · PRAX · CLDX · DNTH

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-13. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-13 Trading days32 Holdings8 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-13, and will update as prices arrive.

Portfolio return-17.00%Buy & hold
QQQ synthetic benchmark-13.72%Liquidity weighted
Excess return-3.28%vs benchmark
Barra annualised vol44.2%Model estimate
Realised vol53.0%Annualised in window
Weighted beta1.03Raw exposure
Factor / specific risk45% / 55%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)77.584.491.398.2105.110-0110-2311-13Logos Global Management LPQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-17.00%Disclosed long book
QQQ synthetic benchmark-13.72%Liquidity-weighted constituents
Model universe, equal weight+0.30%Opportunity-cost reference
Excess return-3.28%Portfolio − benchmark
Arithmetic return sum-16.83%Difference vs compounded is the cross term
Weighted raw beta1.03Weighted holding betas
Realised volatility (annualised)52.99%Daily returns in window
Barra model volatility (annualised)44.19%Factor + specific
Factor share of variance45.3%Barra factors
Specific share of variance54.7%Stock residuals
Reported value$339.7M13F long US equity

2. Return attribution

The -16.83% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +1.65% 9.8%
Momentum & Growth 3 -7.81% -46.4%
Volatility & Tail Risk 7 +0.50% 3.0%
Industry 12 +8.12% 48.2%
Specific 1 -19.30% -114.7%
Return attribution (style + industry, %)-8.8-4.4+0.0+4.4+8.8Short-term Reversal+0.39Turnover+0.48Amihud Illiquidity-0.72Kurtosis+0.80Beta+0.82Leverage (Downside Vol)-0.98Growth-1.31Non-linear Size+1.61Mid Cap-1.97Size+2.28Residual Volatility+6.13Historical Volatility-6.31Momentum-6.89Health Care+8.12
Factor Type Exposure Factor return Contribution Share of |return|
Health Care Industry +1.00 +8.12% +8.12% 48.2%
Residual Volatility Style +2.30 +2.66% +6.13% 36.4%
Size Style -1.25 -1.83% +2.28% 13.6%
Non-linear Size Style +1.76 +0.91% +1.61% 9.6%
Beta Style +0.17 +4.85% +0.82% 4.9%
Kurtosis Style +0.11 +6.97% +0.80% 4.8%
Turnover Style -0.10 -4.77% +0.48% 2.8%
Short-term Reversal Style +0.50 +0.79% +0.39% 2.3%
Max Drawdown Style -0.08 -1.96% +0.15% 0.9%
Skewness Style +0.02 -4.21% -0.11% -0.6%
Amihud Illiquidity Style +1.78 -0.40% -0.72% -4.3%
Leverage (Downside Vol) Style +0.54 -1.82% -0.98% -5.8%
Growth Style -0.84 +1.57% -1.31% -7.8%
Mid Cap Style +1.17 -1.69% -1.97% -11.7%
Historical Volatility Style +0.49 -12.86% -6.31% -37.5%
Momentum Style +2.06 -3.34% -6.89% -40.9%
Specific Specific — — -19.30% -114.7%

3. Risk attribution

Annualised volatility is 44.19%; factor risk explains 45.3% of variance and specific risk 54.7%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-59.1-29.5+0.0+29.5+59.1Growth-0.69Non-linear Size+0.32Beta+0.90Leverage (Downside Vol)+0.92Historical Volatility+1.36Amihud Illiquidity+2.33Mid Cap+2.88Size+4.27Residual Volatility+5.65Health Care+13.40Momentum+13.77Specific+54.69
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 54.7% +24.17% 24.2%
Momentum Style +2.06 13.8% +6.08% 6.1%
Health Care Industry +1.00 13.4% +5.92% 5.9%
Residual Volatility Style +2.30 5.7% +2.50% 2.5%
Size Style -1.25 4.3% +1.88% 1.9%
Mid Cap Style +1.17 2.9% +1.27% 1.3%
Amihud Illiquidity Style +1.78 2.3% +1.03% 1.0%
Historical Volatility Style +0.49 1.4% +0.60% 0.6%
Leverage (Downside Vol) Style +0.54 0.9% +0.41% 0.4%
Beta Style +0.17 0.9% +0.40% 0.4%
Non-linear Size Style +1.76 0.3% +0.14% 0.1%
Growth Style -0.84 -0.7% -0.31% -0.3%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-1.6-0.50.51.62.7Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.25 +2.10 -3.35
Non-linear Size +1.76 +1.68 +0.08
Mid Cap +1.17 +0.13 +1.04
Beta +0.17 +1.29 -1.12
Momentum +2.06 +0.72 +1.35
Short-term Reversal +0.49 -0.64 +1.14
Residual Volatility +2.31 -0.40 +2.71
Historical Volatility +0.49 +0.86 -0.37
Liquidity -0.12 +0.11 -0.23
Amihud Illiquidity +1.78 +1.16 +0.62
Turnover -0.10 +0.21 -0.31
Growth -0.83 +0.58 -1.42
Leverage (Downside Vol) +0.54 +0.14 +0.40
Skewness +0.03 +0.24 -0.21
Kurtosis +0.12 +0.21 -0.10
Max Drawdown -0.08 -0.08 +0.01

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -19.18% +4.32% +14.12% -14.12% +14.12%
Communication Services 0.0% 2.6% +0.00% -15.54% +0.06% +0.41% -0.41% +0.41%
Utilities 0.0% 0.8% +0.00% +11.58% -0.20% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.58% -0.24% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +5.56% -1.66% -0.49% +0.49% -0.49%
Industrials 0.0% 11.1% +0.00% +7.16% -2.27% -0.80% +0.80% -0.80%
Health Care 100.0% 1.7% -17.00% +9.16% +22.08% -0.45% -25.71% -17.16%
Total +21.99% +12.53% -38.70% -4.18%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
RVMD REVOLUTION MEDICINES INC Health Care 36.25% -16.06% -5.82% Reduce
TNGX TANGO THERAPEUTICS INC Health Care 15.79% +2.20% +0.35% Reduce
MDGL MADRIGAL PHARMACEUTICALS INC Health Care 14.83% -15.19% -2.25% New
AVBP ARRIVENT BIOPHARMA INC Health Care 12.03% -57.03% -6.86% Add
GPCR STRUCTURE THERAPEUTICS INC Health Care 9.20% -36.04% -3.32% Add
MAZE MAZE THERAPEUTICS INC Health Care 7.48% +26.31% +1.97% Reduce
CRSP CRISPR THERAPEUTICS AG Health Care 4.07% -23.64% -0.96% Reduce
PTN PALATIN TECHNOLOGIES INC Health Care 0.34% -29.76% -0.10% Reduce
Contribution rank Symbol Sector Weight Return Contribution
1 MAZE Health Care 7.48% +26.31% +1.97%
2 TNGX Health Care 15.79% +2.20% +0.35%
3 PTN Health Care 0.34% -29.76% -0.10%
4 CRSP Health Care 4.07% -23.64% -0.96%
5 MDGL Health Care 14.83% -15.19% -2.25%
6 GPCR Health Care 9.20% -36.04% -3.32%
7 RVMD Health Care 36.25% -16.06% -5.82%
8 AVBP Health Care 12.03% -57.03% -6.86%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-13 (32 trading days), the reported portfolio returned -17.00%, versus -13.72% for the QQQ synthetic benchmark — an excess of -3.28%.
  2. Return attribution: the largest positive style/industry contributions came from Health Care +8.12%, Residual Volatility +6.13%, Size +2.28%; the largest drags came from Momentum -6.89%, Historical Volatility -6.31%, Mid Cap -1.97%. Specific (stock-level) return contributed -19.30%.
  3. Risk attribution: Barra model volatility is 44.19% annualised; factor risk explains 45% of variance and specific risk 55%. The largest factor risk sources are Momentum 13.8%, Health Care 13.4%, Residual Volatility 5.7%.
  4. Style tilt: size -1.25, momentum +2.06, volatility +0.49, liquidity -0.12; the weighted raw beta is 1.03. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +21.99%, selection +12.53% and interaction -38.70%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Logos Global Management LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Logos Global Management LP reported 64 equity positions worth $1.66B in aggregate; its largest disclosed positions were PRAX ($123.77M), RVMD ($123.16M), IDYA ($109.50M).

How large is Logos Global Management LP's portfolio?

Logos Global Management LP reported $1.66B of long equity holdings across 64 positions as of 2026-Q3. Top-10 holdings account for 47.8% of reported value.

What is Logos Global Management LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/logos-global-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →